dehydroepiandrosterone has been researched along with Fatty Liver, Nonalcoholic in 4 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonalcoholic fatty liver disease (NAFLD) is the leading liver chronic disease featuring hepatic steatosis." | 1.62 | The Mitochondrial Trigger in an Animal Model of Nonalcoholic Fatty Liver Disease. ( Aimaretti, E; Aragno, M; Chimienti, G; D'Attoma, B; Lezza, AMS; Orlando, A; Pesce, V; Russo, F, 2021) |
| "Exercise ameliorates nonalcoholic fatty liver disease (NAFLD) by inducing phenotypic changes in Kupffer cells (KCs)." | 1.62 | Prevention of non-alcoholic steatohepatitis by long-term exercise via the induction of phenotypic changes in Kupffer cells of hyperphagic obese mice. ( Komine, S; Miura, I; Mizokami, Y; Oh, S; Okada, K; Shoda, J; Suzuki, H; Uchida, F; Wada, S; Warabi, E, 2021) |
| "Type 2 diabetes is clinically associated with progressive necroinflammation and fibrosis in nonalcoholic steatohepatitis (NASH)." | 1.56 | AGER1 downregulation associates with fibrosis in nonalcoholic steatohepatitis and type 2 diabetes. ( Ali, M; Charville, GW; Das, S; Dehnad, A; Fan, W; Fish, SR; Jiang, JX; Li, Y; Mozes, G; Olson, KA; Török, NJ; Wong, KA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chimienti, G | 1 |
| Orlando, A | 1 |
| Russo, F | 1 |
| D'Attoma, B | 1 |
| Aragno, M | 1 |
| Aimaretti, E | 1 |
| Lezza, AMS | 1 |
| Pesce, V | 1 |
| Dehnad, A | 1 |
| Fan, W | 1 |
| Jiang, JX | 1 |
| Fish, SR | 1 |
| Li, Y | 1 |
| Das, S | 1 |
| Mozes, G | 1 |
| Wong, KA | 1 |
| Olson, KA | 1 |
| Charville, GW | 1 |
| Ali, M | 1 |
| Török, NJ | 1 |
| Miura, I | 1 |
| Komine, S | 1 |
| Okada, K | 1 |
| Wada, S | 1 |
| Warabi, E | 1 |
| Uchida, F | 1 |
| Oh, S | 1 |
| Suzuki, H | 1 |
| Mizokami, Y | 1 |
| Shoda, J | 1 |
| Koehler, E | 1 |
| Swain, J | 1 |
| Sanderson, S | 1 |
| Krishnan, A | 1 |
| Watt, K | 1 |
| Charlton, M | 1 |
4 other studies available for dehydroepiandrosterone and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
The Mitochondrial Trigger in an Animal Model of Nonalcoholic Fatty Liver Disease.
Topics: Animals; Antioxidants; Autophagy; Dehydroepiandrosterone; Diet, High-Fat; Disease Models, Animal; DN | 2021 |
AGER1 downregulation associates with fibrosis in nonalcoholic steatohepatitis and type 2 diabetes.
Topics: Animals; Ascorbic Acid; Cholecalciferol; Dehydroepiandrosterone; Diabetes Mellitus, Type 2; Disease | 2020 |
Prevention of non-alcoholic steatohepatitis by long-term exercise via the induction of phenotypic changes in Kupffer cells of hyperphagic obese mice.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cells, Cultured; Dehydroepiandrost | 2021 |
Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients.
Topics: Adiponectin; Biomarkers; Dehydroepiandrosterone; Fatty Liver; Female; Growth Hormone; Humans; Liver | 2012 |